Latest Period
Q1 2026
Security Snapshot
Protara Therapeutics, Inc. - Common Stock (TARA) Institutional Ownership
CUSIP: 74365U107
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
113
Shares (Excl. Options)
45,561,119
Price
$5.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- TARA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 45,561,119
- Total 13F value
- $237,379,393
- Portfolio coverage rank
- 0%
- Share change
- +5,228,980
- Value change
- +$26,680,319
- Number of holders
- 113
- Shares outstanding
- 54,239,698
- SEC-reported price per share
- $5.13
- Insider filing price
- $5.13
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TARA - Protara Therapeutics, Inc. - Common Stock is tracked under CUSIP 74365U107.
- 113 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 104 to 113 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $212,258,036 to $237,379,393.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 113 institutions filings for Q1 2026.
Security key
74365U107
Latest holder period
Q1 2026
13F holders
113
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
TARA full holder history
Protara Therapeutics, Inc. SEC filings
Protara Therapeutics, Inc. company facts
Protara Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74365U107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
TARA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9.6% | -4% | $27,128,527 | +$340,708 | 5,207,011 | +1.3% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| BlackRock, Inc. | 6.3% | +32% | $17,648,661 | +$5,098,459 | 3,387,459 | +41% | BlackRock, Inc. | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC | 5.1% | $19,314,617 | 2,759,231 | Millennium Management LLC | 25 Feb 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | -50% | $5,974,448 | -$4,423,642 | 1,971,765 | -43% | RA Capital Management, L.P. | 30 Jun 2025 |
| Opaleye Management Inc. | 4.7% | -12% | $7,473,600 | -$410,400 | 1,730,000 | -5.2% | Opaleye Management, Inc. | 31 Mar 2025 |
| CITADEL ADVISORS LLC | 4.7% | $7,031,811 | 1,627,734 | Kenneth Griffin | 31 Dec 2024 | |||
| Woodline Partners LP | 3.9% | $5,751,035 | 1,331,258 | Woodline Partners LP | 31 Dec 2024 |
As of 31 Mar 2026, 113 institutional investors reported holding 45,561,119 shares of Protara Therapeutics, Inc. - Common Stock (TARA). This represents 84% of the company’s total 54,239,698 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 9.6% | 5,207,011 | +1.3% | 0.01% | $27,154,562 |
| BlackRock, Inc. | 6.3% | 3,394,968 | +41% | 0% | $17,687,784 |
| Velan Capital Investment Management LP | 5.2% | 2,834,652 | 0% | 9.3% | $14,768,537 |
| MILLENNIUM MANAGEMENT LLC | 5.2% | 2,831,208 | +276% | 0.01% | $14,750,594 |
| Blackstone Inc. | 4.2% | 2,265,514 | +19% | 0.05% | $11,803,328 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 2,119,018 | 0% | 0% | $11,040,084 |
| Sio Capital Management, LLC | 3.6% | 1,969,839 | +15% | 1.5% | $10,262,861 |
| ACORN CAPITAL ADVISORS, LLC | 3.2% | 1,752,115 | 0% | 2.6% | $9,128,519 |
| Integral Health Asset Management, LLC | 3.2% | 1,750,000 | -22% | 0.48% | $9,117,500 |
| AIGH Capital Management LLC | 3% | 1,622,733 | 1.7% | $8,454,439 | |
| UBS Group AG | 2.6% | 1,402,413 | +15% | 0% | $7,306,572 |
| 5AM Venture Management, LLC | 2.5% | 1,369,782 | 0% | 2% | $7,136,564 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,177,200 | +44% | 0% | $6,134,752 |
| Point72 Asset Management, L.P. | 2.1% | 1,152,714 | +4001% | 0.01% | $6,005,640 |
| CITADEL ADVISORS LLC | 2% | 1,068,558 | +19% | 0% | $5,567,188 |
| Patient Square Capital LP | 1.9% | 1,030,846 | 0.95% | $5,370,708 | |
| STATE STREET CORP | 1.9% | 1,005,142 | +76% | 0% | $5,236,790 |
| BAKER BROS. ADVISORS LP | 1.8% | 971,614 | 0% | 0.03% | $5,062,109 |
| ADAR1 Capital Management, LLC | 1.7% | 940,512 | -17% | 0.3% | $4,900,068 |
| BANK OF AMERICA CORP /DE/ | 1.7% | 925,918 | +87% | 0% | $4,824,033 |
| J. Goldman & Co LP | 1.6% | 856,247 | 0.21% | $4,461,047 | |
| Catalio Capital Management, LP | 1.1% | 580,024 | -60% | 0.63% | $3,021,925 |
| Assenagon Asset Management S.A. | 1% | 567,621 | +84% | 0% | $2,957,305 |
| MORGAN STANLEY | 1% | 556,974 | +218% | 0% | $2,901,834 |
| DIMENSIONAL FUND ADVISORS LP | 0.98% | 531,267 | +134% | 0% | $2,766,593 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 45,561,119 | $237,379,393 | +$26,680,319 | $5.21 | 113 |
| 2025 Q4 | 39,827,589 | $212,258,036 | +$73,099,595 | $5.33 | 104 |
| 2025 Q3 | 26,208,473 | $113,965,432 | -$10,353,742 | $4.35 | 79 |
| 2025 Q2 | 29,714,732 | $90,054,436 | +$447,680 | $3.03 | 76 |
| 2025 Q1 | 28,759,849 | $123,767,729 | -$8,349,026 | $4.26 | 59 |
| 2024 Q4 | 29,670,168 | $156,599,526 | +$91,818,405 | $5.28 | 60 |
| 2024 Q3 | 10,445,706 | $19,115,471 | +$384,364 | $1.83 | 33 |
| 2024 Q2 | 10,449,817 | $22,236,374 | +$12,029,265 | $2.08 | 38 |
| 2024 Q1 | 4,570,660 | $18,342,843 | +$911,041 | $4.01 | 34 |
| 2023 Q4 | 4,357,920 | $8,168,237 | -$1,261,027 | $1.88 | 30 |
| 2023 Q3 | 5,117,943 | $8,547,441 | -$31,849 | $1.67 | 31 |
| 2023 Q2 | 5,136,537 | $12,262,078 | -$1,134,644 | $2.39 | 28 |
| 2023 Q1 | 5,503,158 | $16,886,987 | +$77,617 | $3.13 | 28 |
| 2022 Q4 | 5,478,113 | $14,679,319 | -$481,288 | $2.68 | 29 |
| 2022 Q3 | 5,656,228 | $16,718,296 | -$789,370 | $2.96 | 26 |
| 2022 Q2 | 5,927,042 | $18,391,293 | -$2,063,463 | $2.93 | 31 |
| 2022 Q1 | 6,495,468 | $33,192,511 | -$1,990,162 | $5.11 | 34 |
| 2021 Q4 | 6,872,165 | $46,492,675 | +$3,840,591 | $6.75 | 36 |
| 2021 Q3 | 6,311,961 | $43,679,692 | -$8,598,514 | $6.92 | 36 |
| 2021 Q2 | 7,110,843 | $69,259,000 | -$22,850,218 | $9.74 | 38 |
| 2021 Q1 | 8,528,460 | $134,015,000 | -$11,645,346 | $15.74 | 49 |
| 2020 Q4 | 8,775,745 | $212,476,065 | -$5,829,365 | $24.21 | 48 |
| 2020 Q3 | 9,281,283 | $156,208,097 | +$91,825,921 | $16.83 | 44 |
| 2020 Q2 | 3,696,566 | $108,380,809 | +$108,380,809 | $29.32 | 31 |